Track record · closed signal

Novartis AG (NVS) — closed signal from February 28, 2026

Missed Published before the outcome was known, scored automatically when the window closed on May 29, 2026.

Predicted vs. what happened

NVS price · publication thesis → realized outcomesplit-adjusted

$165.00 – $170.00Entry zone — fair-value band

$168.61Published — price the day we called it

$182.10Target — the price the thesis aimed for

$167.61Peak — highest point inside the window, not a realized return

$151.40Window close — end-of-window price, context only

What happened

Missed

Never rose above the publication price inside the window.

Peak price

$167.61

peak on March 2, 2026 — not a realized return

Peak gain

-0.6%

peak, from the publication price

Window close

$151.40

end-of-window price, context only

Days to target

—

Window

February 28, 2026 – May 29, 2026

The thesis — published February 28, 2026

Predicted growth

+8%

over the measurement window

Target price

$182.10

the price the thesis aimed for

Entry zone

$165.00 – $170.00

the fair-value band we waited for

Price at publication

$168.61

published February 28, 2026

Confidence

78%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novartis looks like a safer healthcare choice for the next few months. The stock has been drifting upward and often draws money when investors become picky. A new radioligand factory plan shows the company is investing in an important area, which helps mood around the stock. Expect gradual gains more than a sudden jump. Watch for regulatory news or trial setbacks.

Primary drivers

New radioligand plant signals real commitment to that business
Drug makers often keep value in uncertain markets
A steady price pattern lets you buy dips with discipline
Pipeline updates can slowly improve investor sentiment

How it played out

NVS: the thesis did not play out

Lyra published NVS on 2026-02-28 at 168.61, with an expected gain of 8% over the short-term window. The thesis expected gradual gains rather than a sudden jump. It pointed to the new radioligand plant plan, defensive demand for drug makers in uncertain markets, a steady price pattern, and possible pipeline updates.

Inside the window, the stock never reached the 182.1 target. Its peak was 167.61 on 2026-03-02, with a peak gain of -0.6%. It ended the window at 151.4 on 2026-05-29. The thesis missed.

What happened during the window

On 2026-03-20, Novartis agreed to buy an experimental breast-cancer drug from Synnovation Therapeutics in a deal valued at up to $3 billion. On 2026-04-28, Novartis reported first-quarter results, and Investors.com said sales fell 5% to $13.11 billion while the company kept its 2026 outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVS signals